These were my notes from the KEI intervention on Tuesday, May 10, 2022, at WIPO SCCR 42, on the proposed WIPO broadcasting treaty. This is essentially a related rights treaty, and goes far beyond the control of signal piracy. And… Continue Reading
On March 18, 2022, Pfizer filed a 45 page opposition to the KEI application for a compulsory license on Paxlovid patents in the Dominican Republican. This is the Pfizer filing, and KEI’s unofficial translation. Pfizer-opposition-DR-CL-18March2022.pdf Translation-Pfizer-opposition-KEI-CL-Paxlovid-18march2022.pdf The December 3, 2021… Continue Reading
See also the following essays in Medium: The proposed WTO agreement on intellectual property and COVID 19 vaccines should not require that authorizations of non-voluntary use of patents list all patents covered, Medium, March 17, 2022. The Quad WTO proposal… Continue Reading
https://www.regulations.gov/comment/USTR-2021-0021-0120 Trade related aspects of public goods Submission to USTR and the Trade Policy Staff Committee (TPSC) James Love, KEI March 8, 2022 Introduction One can think of the economy as including both public and private goods, each valued by… Continue Reading
(More on this topic here: https://www.keionline.org/xtandi2021) On February 24, 2022, Senators Thom Tillis and Marsha Blackburn sent a letter to HHS Secretary Xavier Becerra (PDF copy). The letter refers to “petitions to march-in on a pharmaceutical product purely based on… Continue Reading
This is a letter from the three prostate cancer patient petitioners to HHS Secretary Becerra and Acting NIH Director Tabak, regarding the February 9, 2020 statement by Astellas on the Bayh-Dole march in and government rights case. The patient’s letter… Continue Reading
The Special 301 Subcommittee of the Trade Policy Staff Committee has sent a document with questions to everyone who provided comments on the Special 301 list. The questions are attached and are also available at https://www.regulations.gov/comment/USTR-2021-0021-0065. The deadline to submit… Continue Reading
Senators Elizabeth Warren (D-MA) and Angus King (I-ME) and Representative Lloyd Doggett (D-TX) wrote Secretary of HHS Xavier Becerra on February 17, 2022, urging him to move forward with the march-in petition by Robert Sachs, Clare Love and Eric Sawyer,… Continue Reading
(More on the Xtandi case here: https://www.keionline.org/xtandi2021) Astellas has issued a statement, dated February 9, 2022, on the Bayh-Dole Act and the petition to exercise march-in and government use rights in the prostate cancer drug Xtandi. It was brought to… Continue Reading
In a January 31, 2022 letter to Drew Hirshfeld, the Commissioner for Patents for the USPTO, and Janet Woodcock, the Acting Commissioner of the FDA, Senator Thom Tillis provides extensive criticism of the empirical work of the group I-MAK and… Continue Reading